Omarigliptin

Drug Profile

Omarigliptin

Alternative Names: Marizev; MK-3102

Latest Information Update: 19 Apr 2017

Price : $50

At a glance

  • Originator Merck & Co
  • Class 2 ring heterocyclic compounds; Antihyperglycaemics; Fluorobenzenes; Pyrazoles; Pyrrolidines; Small molecules; Sulfonamides
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus

Most Recent Events

  • 06 Apr 2017 Merck terminates a phase III trial for Type-2 diabetes mellitus due to business reasons in USA, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, the Netherlands, Norway, Slovakia, Poland, Spain and Sweden (NCT01703208)
  • 20 Feb 2017 Merck re-initiates enrolment in a phase III trial for Type-2 diabetes mellitus in USA, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, the Netherlands, Norway, Slovakia, Poland, Spain and Sweden (NCT01703208)
  • 31 May 2016 Merck terminates a phase III trial for Type-2 diabetes mellitus in USA, Austria, Belgium, Croatia, Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, Lithuania, the Netherlands, Poland, Spain and Sweden due to business reasons (NCT01703208)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top